Here we host blogs and tweets about our work and other related topics of interest. If you like and would like to blog with us, send us an email and let us know.

Blogs Latest Blogs

Unresolved non-adherence drives early 2nd line ART failure

Author: Christopher Hoffmann - 2013-08-23

Current guidelines for the management of virological failure recommend excluding drug interactions and inter-current infections, intensifying adherence support and switching to second-line ART if a patient remains viraemic. The aim being to ensure that non-adherent patients receive appropriate adherence support and those with resistance switch regimens.

Figure 2: First-line antiretroviral therapy drug concentrations in stored plasma samples taken prior to switching to second-line antiretroviral therapy

This study highlights that ongoing non-adherence remains a major contributor to first-line virological failure when switching regimens with 55% of patients in this study having sub-therapeutic first-line drug concentrations pre-switch. Perhaps unsurprisingly, these patients were less likely to achieve viral suppression once switched to second-line ART. Furthermore, resistance to NRTIs did not increase risk of first-line failure. In fact, overall patients with resistance did better, perhaps because it reflected a higher degree of adherence. These findings suggest that efforts to intensify adherence support when switching regimens are often unsuccessful and lead to sub-optimal second-line outcomes.

Sub-therapeutic drug concentrations also influenced the patterns of resistance mutations observed at switch; NRTI mutations were detected in 97% of patients on 'therapeutic' first-line ART, compared to 31% on a 'sub-therapeutic' regimen. In particular 47% versus 18% had >1 TAM detected and 26% versus 13% NRTI cross-resistance mutations.

The findings from this study indicate that it is unresolved non-adherence at time of switch, not NRTI resistance, which drives early second-line failure. These findings underline the need to develop simple point-of-care tools for reliably identifying patients in whom non-adherence continues to contribute to viraemia, including options such as simple bio-assays for therapeutic drug levels or other robust measures of adherence. Drug resistance assays at the time of first-line failure appear to be mostly useful to assess adherence, but not for guiding ART management.

Open Access publication:

Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Viral suppression following switch to second-line antiretroviral therapy: associations with NRTI resistance and sub-therapeutic drug concentrations prior to switch. J Infect Dis. 2013 Aug 13. [Epub ahead of print]

15 minutes, All blogs...

Bioinformaticians are pioneering the future of science
From Yumna Moosa, date: 2017-07-28

Meeting of the Swiss, Swedes and South Africans minds
From Nicolette Crozier, Benjamin Chimukangara, Veron Ramsuran, date: 2017-07-25

Megan Druce: from Cum Laude MSc to a Scholarship for a PhD in Germany...
From Megan Druce, date: 2016-04-18

15 minutes, All blogs...

Page design updated by Prof. Tulio de Oliveira, 2015